独家专访恒瑞医药张连山:在慢病管理上的在研产品数量已超肿瘤药,恒瑞转型的决心是极大的|上海药圈新拐点

科Way
Nov 17, 2025

四年前,市场对A股“药茅”恒瑞医药的未来曾一度产生分歧;四年后的今天,公司的发展轨迹已给出清晰回应。短短几年间,恒瑞完成了V型反转——今年半年报业绩刷新历史纪录;签出120亿美元“天价”出海大单;成功登陆港交所,募资超百亿港元……对于这一切,市场用“杀疯了”来形容恒瑞。值得注意的是,就在今年10月末,恒瑞医药位于张江总部经济园区的上海创新研发中心正式启用,成为上海与国内创新龙头企业双向奔赴的又一...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10